-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, Osaikang issued an announcement stating that the company’s application for clinical trial of the new drug ASKG712 injection has been accepted.
This product is a class 1 biological new drug independently developed by the company and is intended to be used for the treatment of various retinal diseases such as nAMD (wet age-related macular degeneration).
), DME (diabetic macular edema) and RVO-ME (macular edema caused by retinal vein occlusion in adult patients).
At present, no product with the same target has been approved for marketing at home and abroad
.
Figure 1: The latest product information declared by Osaikon
Source: CDE official website
The announcement mentioned that ASKG712 injection can block the VEGF/VEGFR signal and effectively control the formation of new blood vessels, while also inhibiting the Ang-2 signal to improve blood vessel stability and reduce retinal inflammation, and consolidate the therapeutic effect of anti-VEGF-A
.
Compared with anti-VEGF therapy alone, ASKG712 injection is expected to significantly reduce the frequency of ocular injections, improve patient compliance, and achieve better therapeutic effects
Figure 2: The scale of the domestic ophthalmic drug market in recent years (unit: ten thousand yuan)
Source: Mi Nei Net Database
AMD is a disease in which the central vision of the retina in the macular area is progressively decreased, and it is one of the major blinding eye diseases in adults over 50 years of age
.
There are approximately 21.
Figure 3: 2021H1 ocular vascular disease treatment drug product layout
Source: Mi Nei.
The terminal of public medical institutions in China is the main battlefield of ophthalmic drugs.
It is worth mentioning that the product declared this time is the second biological class 1 new drug of Osaikang.
Figure 4: Clinical progress of ASKB589 injection
Source: China Drug Clinical Trial Publicity Library of Meinenet
Source: CDE official website, company announcement, Minet database
Clinical data statistics are as of October 27th, please correct me if there are any errors or omissions
